Carnegie Investment Counsel Decreases Stock Holdings in STERIS plc $STE

Carnegie Investment Counsel reduced its position in shares of STERIS plc (NYSE:STE) by 6.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 53,192 shares of the medical equipment provider’s stock after selling 3,505 shares during the quarter. Carnegie Investment Counsel owned about 0.05% of STERIS worth $13,162,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of STE. Orbis Allan Gray Ltd bought a new position in STERIS during the first quarter valued at $349,950,000. Norges Bank purchased a new stake in shares of STERIS during the 2nd quarter valued at about $289,132,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of STERIS by 55.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider’s stock valued at $344,617,000 after buying an additional 540,999 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of STERIS by 32.2% in the 2nd quarter. Invesco Ltd. now owns 1,220,699 shares of the medical equipment provider’s stock valued at $293,236,000 after acquiring an additional 297,076 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in STERIS by 305.9% in the third quarter. Assenagon Asset Management S.A. now owns 330,907 shares of the medical equipment provider’s stock worth $81,880,000 after acquiring an additional 249,386 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on STE. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $273.50.

Insider Activity at STERIS

In related news, VP Julia Madsen sold 5,008 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the transaction, the vice president owned 10,710 shares of the company’s stock, valued at $2,806,020. This trade represents a 31.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the sale, the vice president owned 5,695 shares of the company’s stock, valued at $1,466,747.25. The trade was a 46.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 25,203 shares of company stock valued at $6,624,667. Company insiders own 1.07% of the company’s stock.

STERIS Stock Down 0.2%

Shares of NYSE:STE opened at $255.29 on Friday. The firm has a market capitalization of $25.06 billion, a PE ratio of 36.68 and a beta of 1.01. The business has a 50 day simple moving average of $254.28 and a two-hundred day simple moving average of $244.57. STERIS plc has a 1 year low of $200.98 and a 1 year high of $268.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a return on equity of 14.43% and a net margin of 12.07%.The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same period last year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, equities analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, November 18th. STERIS’s payout ratio is currently 36.21%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.